Exploring the Role of DARPP-32 in Addiction: A Review of the Current Limitations of Addiction Treatment Pathways and the Role of DARPP-32 to Improve Them

Overview

Journal NeuroSci

Specialty Neurology

Date 2024 Nov 1

PMID 39483434

Authors

Megan R Greener

Sarah J Storr

Affiliations

Soon will be listed here.

Abstract

We are amidst a global addiction crisis, yet stigmas surrounding addiction counterintuitively prevail. Understanding and appreciating the neurobiology of addiction is essential to dissolve this stigma and for the development of new pharmacological agents to improve upon currently narrow therapeutic options. This review highlights this and evaluates dopamine-and-cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32) as a potential target to treat various forms of substance abuse. Despite the proven involvement of DARPP-32 in addiction pathophysiology, no robust investigations into compounds that could pharmacologically modulate it have been carried out. Agents capable of altering DARPP-32 signalling in this way could prevent or reverse drug abuse and improve upon currently substandard treatment options.

References

Bibb J, Snyder G, Nishi A, Yan Z, Meijer L, Fienberg A . Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999; 402(6762):669-71. DOI: 10.1038/45251. View

Littleton J, Zieglgansberger W . Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict. 2004; 12(s1):s3-s11. DOI: 10.1111/j.1521-0391.2003.tb00492.x. View

Wang H, Farhan M, Xu J, Lazarovici P, Zheng W . The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget. 2017; 8(32):53791-53803. PMC: 5581150. DOI: 10.18632/oncotarget.17339. View

Borgkvist A, Marcellino D, Fuxe K, Greengard P, Fisone G . Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol. Neuropharmacology. 2007; 54(1):31-5. DOI: 10.1016/j.neuropharm.2007.06.025. View

Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn A, Greengard P . Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A. 2005; 102(4):1199-204. PMC: 545831. DOI: 10.1073/pnas.0409138102. View

Zwar N, Mendelsohn C, Richmond R . Supporting smoking cessation. BMJ. 2014; 348:f7535. DOI: 10.1136/bmj.f7535. View

Lindskog M, Svenningsson P, Fredholm B, Greengard P, Fisone G . Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur J Neurosci. 1999; 11(6):2182-6. DOI: 10.1046/j.1460-9568.1999.00597.x. View

Connor J, Stjepanovic D, Le Foll B, Hoch E, Budney A, Hall W . Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021; 7(1):16. PMC: 8655458. DOI: 10.1038/s41572-021-00247-4. View

Konsolaki E, Skaliora I . Motor vs. cognitive elements of apparent "hyperlocomotion": a conceptual and experimental clarification. Proc Natl Acad Sci U S A. 2014; 112(1):E3-4. PMC: 4291628. DOI: 10.1073/pnas.1413820112. View

10.

Saidy B, Kotecha S, Butler A, Rakha E, Ellis I, Green A . PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression. J Cell Mol Med. 2021; 25(11):5015-5024. PMC: 8178272. DOI: 10.1111/jcmm.16447. View

11.

McGinty E, Barry C . Stigma Reduction to Combat the Addiction Crisis - Developing an Evidence Base. N Engl J Med. 2020; 382(14):1291-1292. DOI: 10.1056/NEJMp2000227. View

12.

Hemmings Jr H, Greengard P, Tung H, Cohen P . DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984; 310(5977):503-5. DOI: 10.1038/310503a0. View

13.

Hall W, Stjepanovic D, Caulkins J, Lynskey M, Leung J, Campbell G . Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet. 2019; 394(10208):1580-1590. DOI: 10.1016/S0140-6736(19)31789-1. View

14.

Dupre K . A potential neuroanatomical dissociation of DARPP-32 in striatal ERK signaling. J Neurosci. 2008; 28(43):10783-5. PMC: 6671382. DOI: 10.1523/JNEUROSCI.4160-08.2008. View

15.

Phillips K, Epstein D, Preston K . Psychostimulant addiction treatment. Neuropharmacology. 2014; 87:150-60. PMC: 4524548. DOI: 10.1016/j.neuropharm.2014.04.002. View

16.

Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T . Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol. 2009; 13(9):1175-91. DOI: 10.1017/S1461145709991003. View

17.

Bibb J, Nishi A, OCallaghan J, Ule J, Lan M, Snyder G . Phosphorylation of protein phosphatase inhibitor-1 by Cdk5. J Biol Chem. 2001; 276(17):14490-7. DOI: 10.1074/jbc.M007197200. View

18.

Engmann O, Giralt A, Gervasi N, Marion-Poll L, Gasmi L, Filhol O . DARPP-32 interaction with adducin may mediate rapid environmental effects on striatal neurons. Nat Commun. 2015; 6:10099. PMC: 4675091. DOI: 10.1038/ncomms10099. View

19.

Stotts A, Dodrill C, Kosten T . Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009; 10(11):1727-40. PMC: 2874458. DOI: 10.1517/14656560903037168. View

20.

Risinger F, Freeman P, Greengard P, Fienberg A . Motivational effects of ethanol in DARPP-32 knock-out mice. J Neurosci. 2001; 21(1):340-8. PMC: 6762425. View